Medicus Pharma Ltd. (NASDAQ:MDCX) has submitted an optimized Phase 2 clinical study design to the U.S. Food and Drug Administration (FDA) for Teverelix, its investigational gonadotropin-releasing hormone (GnRH) antagonist. This study aims to prevent recurrent acute urinary retention (AURr) in men suffering from benign prostatic hyperplasia (BPH), addressing a significant clinical need in a market valued at approximately $2 billion. The refined study, led by Dr. Steven A. Kaplan, a prominent figure in urology, seeks to generate actionable clinical data more rapidly and efficiently. The updated design will involve around 126 patients across the United States and Europe and is structured to detect clear pharmacodynamic signals, such as total prostate volume reduction. The study will last 52 weeks, including a 28-week treatment phase and a 24-week follow-up, with an interim analysis planned after 12 weeks to guide future development. This approach aims to reduce overall study size and costs while accelerating the path to commercialization for Teverelix.